Since the general disclosure rule for provider-manufacturer relationships in France was enacted into law on January 1, 2012, its compliance and enforcement have been a common point of discussion for health care professionals, pharmaceutical and medical device manufacturers, and government officials, among others. As Reed Smith partner Daniel Kadar points out in “The French Sunshine Act Continues to Be a Challenge,” an article published in the April 2015 edition of eHealth Law & Policy, the law is viewed by many as a work-in-progress that requires frequent clarification. Daniel attributes this to the “erratic” evolution of the law.

Read more by downloading the .PDF below.